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Abstract: Imbalance in the oxidative status in neurons, along with mitochondrial damage, are com-
mon characteristics in some neurodegenerative diseases. The maintenance in energy production
is crucial to face and recover from oxidative damage, and the preservation of different sources of
energy production is essential to preserve neuronal function. Fingolimod phosphate is a drug with
neuroprotective and antioxidant actions, used in the treatment of multiple sclerosis. This work was
performed in a model of oxidative damage on neuronal cell cultures exposed to menadione in the
presence or absence of fingolimod phosphate. We studied the mitochondrial function, antioxidant
enzymes, protein nitrosylation, and several pathways related with glucose metabolism and glycolytic
and pentose phosphate in neuronal cells cultures. Our results showed that menadione produces
a decrease in mitochondrial function, an imbalance in antioxidant enzymes, and an increase in
nitrosylated proteins with a decrease in glycolysis and glucose-6-phosphate dehydrogenase. All these
effects were counteracted when fingolimod phosphate was present in the incubation media. These ef-
fects were mediated, at least in part, by the interaction of this drug with its specific S1P receptors.
These actions would make this drug a potential tool in the treatment of neurodegenerative processes,
either to slow progression or alleviate symptoms.
Keywords: sphingosine-1-phosphate receptor analogue; fingolimod phosphate; neuroprotection;
mitochondrial damage; glycolytic pathway; pentose phosphate pathway; redox homeostasis
1. Introduction
Energy is a key factor in maintaining brain function, especially for the generation of
action potentials, axonal transport, synthesis and release of neurotransmitters, and synaptic
function. In brain, the main sources of energy are based in the uptake and metabolism
of glucose and oxygen [1], and the choice between one of those may have important
consequences for brain function in both health and disease [2]. Several studies have demon-
strated that many neurodegenerative diseases are triggered or maintained by metabolic
alterations [3,4]. During aging, a certain decrease in glucose and oxygen metabolism can
be seen [3], but a more dramatical decrease is found in disorders such as Alzheimer’s
disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and Hunting-
ton’s disease (HD) [5]. The need of energy to maintain its function and integrity is much
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more manifest in neurons susceptible to degeneration, and therefore the failure in energy
metabolism, along with the enormous energy demand, can eventually result in higher
cellular stress in these neurons [5].
Some neurodegenerative diseases, such as PD, multiple sclerosis (MS), ALS, or AD,
are characterized by an imbalance in the oxidative status of the cells, leading to neuronal
damage and death, contributing to the disease pathogenesis [6]. These pathologies have
in common a mitochondrial damage that in turn increases, even more, the oxidative
damage on the neurons in such way that they could be grouped as mitochondriopathies [7].
In these, and probably in most neurodegenerative diseases, the importance of glycolysis
on synapse, axonal conduction, and plasticity among other neuronal functions has been
previously established [8]. The coexistence of different sources of ATP production, such
as mitochondrial and glycolytic ATP, allows faster adaptative mechanisms to situations
of high energy demand and may help in the maintenance of neuronal function in stress
situations [9]. A clearer knowledge of the influence of the oxidative damage on these
pathways could be crucial in the development of potential therapeutic strategies targeting
these diseases [10].
Fingolimod is one of the few drugs available orally for treatment of MS; after phospho-
rylation, it is converted into fingolimod phosphate (FP), the active part of the compound.
Recent works have indicated a neuroprotective effect of this drug that could promote
an improvement in cognitive function in ischemic processes [11] and neurodegenerative
disorders such as HD [12] or AD [13].
Several external and/or internal noxious stimuli are able to produce neuronal damage
that in most occasions triggers an imbalance in the neuronal oxidative homeostasis, result-
ing in most cases in accumulation of oxygen free radicals that damage proteins, nucleic
acids, and lipid membranes, leading to neuronal death [10]. To study neuronal dysfunction,
we used a model based in the increase of endogenous reactive oxygen species (ROS) pro-
duction, induced by the treatment of cells with the toxin menadione (VitK3) [14–16]. VitK3
is an exogenic toxin that produces mitochondrial damage linked to an increase in ROS [17],
distorting cellular structures such as the endoplasmic reticulum, but also influencing im-
portant metabolic pathways such as glycolysis and/or pentose phosphate (PPP) [18]. VitK3
interferes in the quinone redox-cycle, uncoupling the mitochondrial respiratory chain, trig-
gering the release of O2−• that in the presence of Fe from the respiratory complex produces
an increase in free radicals [17], with an increase in respiration without the increase in ATP
production. Furthermore, oxidative stress could also activate/inactivate other metabolic
pathways that may contribute to VitK3 damage [19].
In the present work, we resorted to the analysis of glucose metabolism pathways
(glycolysis and pentose phosphate (PPP)), along with mitochondrial respiration, in order
to investigate the molecular events associated with the protective effect of fingolimod
against VitK3-induced oxidative cell damage in SN4741 neuronal cells. The results of this
work will provide an insight into the underlying mechanisms in oxidative damage and
neuroprotection.
2. Materials and Methods
2.1. Cell Culture and Treatments
The SN4741 (RRID:CVCL_S466) dopaminergic cell line derived from mouse substantia
nigra [20] were cultured in D-MEM high glucose supplemented with 10% FCS, penicillin–
streptomycin, and L-glutamine (Fisher Scientific SL, Madrid, Spain), which were incubated
at 37 ◦C in 5% CO2 up to about 70–80% confluence. Cells were seeded in a 100 mm2
dish (5 × 106 cells) or glass bottom 35 mm2 dish and 6-well plates (2 × 105 cells each)
and treated with 5 µM of VitK3 (CAS nº 58-27-5; Sigma, Madrid, Spain) in the absence
or presence of 50 nM FP; this concentration was established in a previous work of our
group [17], based in experiments on the toxicity of the drug in a range from 0.1 to 100 nM
on control cultures, and experiments where different concentrations of FP were tested for
the ability to protect neuronal cultures against the damage produced by Vitk3, assessed
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by cell viability. In order to obtain a tighter control on the concentration of drug in the
culture media, in this work, we used in all the incubations of the active metabolite FP
kindly provided by Novartis Pharmaceutical, instead of the prodrug. The sphingosine-
1-phosphate (S1P) receptor antagonist W123 (W) 10 µM (CAS nº 1345982-24-2. Cayman
Chemicals, Michigan, USA) was also co-incubated with VitK3 and FP. The treatments
were carried out in Locke’s solution (modified) (137 mM NaCl, 5 mM CaCl2, 10 mM KCl,
25 mM glucose, 10 mM HEPES, pH 7.4) supplemented with penicillin–streptomycin and
L-glutamine during 2 h at 37 ◦C. In some experiments, such as extracellular acidification
rate (ECAR) and oxygen consumption rate (OCR), the incubation time was extended over
4 additional hours. In ECAR experiments, dishes, plates, and coverslips were pre-coated
with poly-D-lysine. The groups studied in this work were control cells without treatment
(CO), cells incubated in the presence of VitK3 (VitK3), cells treated with VitK3 in the
presence of FP (VitK3+FP), cells treated with VitK3 in the presence of FP and the antagonist
of S1P receptor W (VitK3+FP+W), and cells incubated only in the presence of FP (FP). In
some experiments, performed to assess the effect of FP in the recovery of VitK3 damage,
after incubation of 2 h with VitK3, the buffer was changed by only buffer (in control cells)
or buffer with 50 nM FP (treated cells) and the same but in the presence of 10 µM W to
clarify the contribution of the S1P receptor on this recovery; measurements were obtained
over 4 additional hours.
2.2. Antioxidant Enzyme Activity
Antioxidant enzyme activity of superoxide dismutase (SOD; E.C.1.15.1.1), glutathione
peroxidase (E.C.1.11.1.9) (GPX), and catalase (E.C.1.11.1.6) (CAT) was measured spectropho-
tometrically using a Cobas Mira autoanalyzer (ABX Diagnostics, Montpellier, France) and
the different commercial kits described previously [21].
2.3. Protein Nitrosylation
Protein nitrosylation was measured in a homogenate of neuronal cultures using the
commercial kit OxiSelect Nitrotyrosine ELISA Kit (Cell Biolabs, Inc., San Diego, CA, USA)
following the supplier instructions.
2.4. Determination of Aldolase
Aldolase activity (EC 4.1.2.13) in cell homogenates was assessed using an Aldolase
assay kit (Spinreact SP, Gerona, Spain) adapted to a Cobas Mira Autoanalyzer. This assay
was based on the observation of the decrease in absorbance at 340 nm caused by the
conversion of NADH to NAD+ [22].
2.5. Glucose-6-Phosphate-Dehydrogenase Activity
Glucose-6-phosphate-dehydrogenase (EC 1.1.1.49) (G-6-PDH) activity in cell ho-
mogenates was assessed using a G-6-PDH assay kit (Spinreact SP, Gerona, Spain) adapted
to a Cobas Mira Autoanalyzer. This assay was based on the observation of the decrease in
absorbance at 340 nm caused by the conversion of NADPH to NADP+ [22].
2.6. Extracellular Acidification Rate (ECAR) and Mitochondrial Oxygen Consumption Rate
(OCR)
Proton excretion (glycolysis) produces rapid changes in the concentration of free pro-
tons in culture media; this change was measured as ECAR, using microplates in a Seahorse
Bioscience XF24 analyzer (Agilent Technologies. Agilent, CA, USA). OCR was measured
using the same instrument [23,24]. Cells were seeded at 2 × 104 cells per well for 18 h
prior to the analysis, and each experimental condition was performed on 8 replicates.
Before each measurement, the cells were washed with PBS, and 590 µL of Agilent Sea-
horse XF Base Medium (without phenol red and bicarbonate) supplemented with 1 mM
pyruvate and 25 mM glucose was added to each well. Measurements were normalized
according to protein concentration in each well. For OCR experiments, we used the com-
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mercial kit “Seahorse XF cell Mito Stress test kit” (Agilent Technologies. Agilent, CA, USA)
following the manufacturer’s instructions; this kit uses oligomycin, carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP), and rotenone/antimycin as mitochondrial
toxins. For the study of different situations of ECAR we used to uncouple mitochondrial
respiration from ATP synthesis, we used 2,4-dinitrophenol (2,4-DNP); 2-deoxy-D-glucose
(2-DG) was used to inhibit glycolysis and rotenone was used to inhibit NADH hydroge-
nase/complex I [23]. In all the experiments, data were normalized with protein content in
each well, as described previously [25].
2.7. Immunocytochemical Staining
Immunocytochemical staining was performed as described previously [17]. The
primary antibody was Anti-S1P Receptor EDG1 (1:100 v/v) (cat nº SAB4500687, Sigma,
Madrid, Spain) in PBS/3% BSA/0.02% sodium azide, incubated at 4 ◦C overnight. Sec-
ondary antibody was Alexafluor 488 (Fisher Scientific SL, Madrid, Spain), in PBS/BSA,
incubated for 30 min at room temperature in the dark. Images were acquired using an
Olympus BX51 epifluorescence microscope at 40× magnification and processed using
ImageJ software (U.S. National Institute of Health; http://rsbweb.nih.gov/ij/).
2.8. Statistical Analysis
Statistical differences were determined using one-way ANOVA. Pairwise comparisons
were performed using a post hoc Newman–Keuls multiple comparison test. Statistical
significance was considered to be p < 0.05. For data in which the measured units were
arbitrary, the respective values represent the percentage relative to the control value unless
otherwise specified.
3. Results and Discussion
In our work, we resorted to the analysis of glycolytic pathway and PPP, along with
mitochondrial function, in order to study the molecular events responsible of the protective
effect of FP against VitK3-induced oxidative damage. This study was performed on neu-
ronal cell cultures and thus one of the limitations of the work was our failure in knowing
the protective effect of FP in the whole animal. In any case, a clearer knowledge of these
pathways could help to understand the mechanisms involved in oxidative damage, com-
mon in several neurodegenerative diseases, hence allowing for amelioration of symptoms
and/or development of new therapeutic strategies.
On the basis of the importance of glycolysis to maintain neuronal metabolism when
mitochondrial dysfunction appears, along with previous work by our group and others
showing the influence of ROS in energy production by neurons [17,26,27], we decided to
go deeper into the study not only of antioxidant enzymes and mitochondrial function,
but also the effect of FP on glucose metabolism.
3.1. Mitochondrial Function Studies
In order to determine the influence of oxidative radicals on mitochondrial respiration
chain function, we studied the OCR in neuronal cultures after oxidative damage induced
by VitK3 in the presence or absence of FP. VitK3 is a derivative of vitamin K and a redox
cycling agent, and its mechanism of action is well characterized. VitK3 is reduced at the
level of complex I of the mitochondrial respiratory chain, decreasing its activity by 50% [28]
and inhibiting complex IV activity [17] with an increase in respiration without increase in
ATP production and decrease of spare respiratory capacity (SRC) and maximal respiratory
capacity. Bioenergetic assessment is shown in Figure 1; the OCR data obtained in these
experiments enabled the determination of oxygen consumption due to (a) ATP synthesis,
(b) mitochondrial oxygen reserve capacity, (c) related to proton leak, (d) SRC, and (e)
maximal respiration.
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Figure 1. Study of neuronal mitochondrial function after treatment of a cell with menadione (VitK3) in the absence or
presence of fingolimod phosphate (FP). The oxygen consumption rate was assessed in (a) basal after 2 h of incubation
with VitK3; (b) ATP production, measured after additi of olig mycin; (c) proton leak, considered as t e residu l oxygen
consumption after oligomycin addition; (d) spare respiratory capacity (SRC), as the difference b tween maximal respiration
and basal respiration; and (e) maximal respiration, obtained as the oxygen consumption after subsequent addition of
oligomycin and carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP). The sequence of mitochondrial toxins
added was oligomycin, 1 µM; FCCP, 0.5 µM; rotenone/antimycin A, 0.5/0.5 µM. The inclusion of rotenone/antimycin A
served to measure respiration by non-mitochondrial processes as these compounds abolish mitochondrial respiration, and
it was subtracted in all oxygen consumption rate (OCR) values obtained. Values represent mean and SD of at least five
experiments per situation performed in triplicate. (* p < 0.05 versus CO, $ p < 0.05 versus VitK3).
In basal situations (without addition of oligomycin, FCCP, and rotenone/antimycin),
the incubation of neurons with VitK3 showed an increase in OCR of 17% compared to the
control, agreeing with our previous results and others [17,19], whereas neurons incubated
with VitK3 in the presence of FP maintained the same levels as the control cells (Figure 1a).
Mitochondrial ATP-dependent OCR is the OCR required for the synthesis of ATP at
complex V, which can be easily studied as it is sensitive to oligomycin. Regarding oxygen
consumption by mitochondrial ATP synthesis, this decreases by 25% after incubation with
VitK3, agreeing with the results of Lakhter et al. [29], who also found a similar decrease
after incubation with this toxin. In our experiments, FP partially rescued the VitK3-induced
loss of ATP linked to OCR, agreeing with Bai et al. [30], who found that increased ATP
production by FP could be the reason for its neuroprotective effect; in our case, FP restored
OCR linked to ATP production to levels close to control neurons (Figure 1b).
We did not find differences in proton leak (Figure 1c), although we could see a clear
difference in SRC, the difference between OCR at basal and at maximal respiratory activity,
after oligomycin and FCCP addition. In our experiments, incubation of neurons with VitK3
produced a great decrease in SRC (40%) compared to the control, which was reverted to
values close to the control in the presence of FP (Figure 1d).
SRC is essential to maintain neuronal homeostasis against oxidative and/or other
types of cellular stress [31]. The use of mitochondrial SRC by neurons is very variable,
ranging from approximately 6 to 7% in resting situation to up to 80% in firing neurons;
thus, deterioration in mitochondrial SRC can be fatal to neurons [31]. The ability to
increase the SRC by FP will allow mitochondria to produce more ATP and overcome an
increase in oxidative stress imbalance. FP could then be considered a long-term regulator
of mitochondrial respiration through the changes promoted in SRC; this modulation could
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be related to an increase in the expression of neuronal nitric oxide synthase (NOS) and
a consequent increase in nitric oxide (NO) levels [32], agreeing with our results on protein
nitrosylation found in Table 1. These long-term regulators produce permanent changes
in mitochondrial respiration that seem to be tissue-specific [33]. This would make FP a
valuable therapeutic tool in neurodegenerative diseases, such as PD, HD, or MS, in which
imbalance in oxidative stress would produce a dramatical mitochondrial affectation in
such a way that they have been grouped as mitochondriopathies [7,34,35].
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expressed as mean ± SD. (a: p < 0.05 versus CO, b: p < 0.05 versus VitK3, c: p < 0.05 versus VitK3+FP, d: p < 0.05 versus VitK3+FP+W).
We also found a similar result in maximal respiratory activity, which is the maximum
rate of respiration achieved by a neuron after addition of uncoupling FCCP and oligomycin
and an indicator of potential mitochondrial dysfunction [31]. In these experiments, incuba-
tion of neurons with VitK3 produced a clear decrease (32%) in maximal respiratory activity.
This decrease was counteracted by coincubation in the presence of FP, being able to recover
20% of maximal respiratory activity (Figure 1e).
The effect of FP on mitochondrial function could be related to the modulation of
mitochondrial translocator protein expression (TSPO) [36], a mitochondrial membrane
protein associated with the mitochondrial permeability pore that is expressed in all cells of
embryonic origin [37], such as those used in this work; this has been seen in MS, where FP
decreases the expression of TSPO [38], stabilizing mitochondria. Furthermore, we could
not exclude the possibility that PF may regulate the expression of prohibitins, a chaperone
that regulates the mitochondrial respiratory complex assembly and activity [39–42]. There
are also some reports on the protective effect of the stimulation of S1P1 receptor on genes
involved in the expression of proteins that participate in the stabilization of mitochondrial
function [36]. We could also postulate that FP induces an increase of protective factors,
such as the nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that
binds to antioxidant response elements (ARE) in the nucleus, leading to transcription of
ARE genes. FP also facilitates the Nrf2 translocation to the nucleus [17], increasing the
synthesis of mitochondrial enzymes and modulating mitochondrial function; these effects
may delay or ameliorate the damage induced by VitK3 [43]. In all the experiments shown
in Figure 1, control cells were incubated in the presence of FP without any significative
change in the values obtained compared to control cells.
3.2. Antioxidant Enzymes Studies
In the study of enzymes related with O2−• metabolism, we found an increase (77.3%)
of mitochondrial SOD2 activity in VitK3-treated neurons compared to the control (Table 1).
In our experiments, that increase was not compensated by variations in CAT or GPX
activities (see ratio in Table 1).
Increased SOD2 activity would in turn produce an increase in H2O2 that, in order to
maintain homeostasis, should be followed by increases in CAT and/or GPX to remove
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H2O2 excess and avoid oxidative damage. This would suggests that mitochondria are
involved in the generation of oxidative stress triggered by VitK3, agreeing with our previous
results [17]. SOD2 is an inducible mitochondrial enzyme that promotes the formation of
H2O2, with one of the factors that induces its expression being the increase in O2−• [44].
Interestingly, as we found in the experiments, in the presence of FP, the SOD2 activity was
normalized to control levels, indicating that FP, as shown above, exerts a protective effect on
mitochondrial function; it also reduced O2−• production, as demonstrated previously [17],
and both in turn could contribute to the reduction in the induction of SOD2.
GPX is an enzyme family with peroxidase activity that protects cells from oxidative
damage on the basis of its ability to reduce free H2O2 to water at low H2O2 concentrations.
In our experiments, we found a decrease (79.4%) in GPX activity in neurons treated with
VitK3 compared to the control, probably as a consequence of the increase in O2−•/SOD,
decrease in total thiols, and increase in nitrosative stress [45], which exerts actions in parallel
with ROS, as demonstrated previously [17]. In these experiments, the inclusion of FP in the
incubation media partially recovered (50%) the activity of this enzyme, agreeing with the
finding of other authors [46]; this effect could be mediated by the Nrf2 translocation to the
nucleus, as demonstrated previously [17,47].
CAT is an enzyme that efficiently removes H2O2 at high concentrations of the oxidant.
In our experiments, we did not see any modification after incubation with VitK3 alone or
in presence of FP; only in control cells was a clear increase (57%) in CAT activity produced.
This could be related with ability of FP to promote an increase in Nrf2 expression and
translocation demonstrated in a previous work [17].
To assess the putative damage produced by oxidative stress induced by VitK3 treat-
ment, we resorted to the study of protein nitrosylation. The nitrosylation of proteins
triggered by NO is greatly enhanced in presence of O2−• with the formation of peroxini-
trites [48], and it is an important regulator of mitochondrial activity involved in energy-
transducing systems [49]. NO is an important molecule in neuronal cell signaling, but its
overproduction can be toxic to neurons, causing protein nitrosylation and mitochondrial
damage [50]. In our experiments, we found a great increase (almost 600%) in protein
nitrosylation in neurons treated with VitK3; again coincubation in presence of FP restored
nitrosylation to levels close to control neurons, which could be explained by the ability of
FP to inhibit the inducible NO demonstrated previously [12] that in turn would decrease
protein nitrosylation. We also could see an increase in control neurons treated with FP
(246%), which could have been due to the stimulation of neuronal NO [32]; moreover, FP
has been involved in an increase in neuronal plasticity mediated by NO [51,52], although
further studies will be necessary to clarify this point.
3.3. Glucose Metabolism Studies
In neuronal cells, glucose is mainly metabolized via glycolysis, the PPP, and oxida-
tive phosphorylation to produce ATP. Expression of genes associated with plasticity and
synaptic remodeling processes are associated in the adult brain with aerobic glycolysis [9].
Active synapses obtain its energy by glucose breakdown through glycolysis, with this being
the main source of cellular energy, as well as the preferred method for certain neuronal
functions, such as fast axonal transport [53].
In presence of VitK3, we found a great decrease (46% compared to control) in gly-
colysis, measured as ECAR after 2 h of incubation; coincubation in the presence of FP
recovered values to control levels (Figure 2a,b). This effect was similar to that found with
some sphingosine-1-phospate mimetics that increase the expression of genes related with
glycolysis, ECAR, and glycolytic capacity [54]. In the study of glycolytic capacity, which
measures the maximum rate of conversion of glucose to pyruvate or lactate, we found
that VitK3 produced a decrease by 47% compared to the control, with this decrease being
totally reverted by coincubation in the presence of FP (Figure 2a,c). When we studied
the glycolytic reserve, which is the ability of cells to adapt to extra energetic demands
when the glycolytic function is working at maximum, neurons incubated in presence of
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VitK3 also showed a reduction in glycolytic reserve by 48% compared to the control; again,
coincubation in the presence of FP reverted this value to control levels (Figure 2a,d). Our
results partially agree with those from Lee et al. [54], who found an increase of glycolytic
capacity with S1P mimetics in mesenchymal cells, although the authors did not find dif-
ferences in glycolytic reserve, possibly due to the different type of cells. This recovery in
glycolytic capacity would rapidly supply ATP in situations where it is needed and when
the mitochondrial metabolism, although generally having a high capacity to produce ATP,
is not totally functional, as demonstrated previously.
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acidification rate (ECAR) and glycolytic function after incubation with VitK3 in the presence or absence of FP (blue line:
CO; red line: VitK3; green line: VitK3+FP; purple line: VitK3+FP+W). To uncouple mitochondrial respiration from ATP
synthesis, we us d 2,4-dinitrophenol (2,4-DNP) 100 µM; 2-deoxy-D-glucose (2-DG) 100 mM was used to inhibit glycolysis
and rote one 1 µM was use to inhibit NADH hydrogenase/c mplex I. (b) Basal glycolysis after 2 h f treatment with VitK3
in the presence or absence of FP. (c) Glycolytic capacity obtained after incubation with 2,4-DNP and rotenone. (d) Glycolytic
reserve obtained as the difference between the maximal glycolytic capacity and basal. In all situations, the non-glycolytic
ECAR, obtained after addition of rotenone, was subtracted. Values represent mean and SD of at least five experiments per
situation perform d n tr plicate. (* p < 0.05 versus CO, $ p < 0.05 versus VitK3, # p < 0.05 versus VitK3+FP, & p < 0.05 versus
VitK3+FP+W).
As mentioned above, we found an increase in the expression of metabolic pathway
related to glycolysis. This has also been described before in situations of energy stress,
where increase in glycolytic metabolic enzymes have been seen in presynaptic buttons [55].
The decrease in glycolytic enzyme activity as a consequence of oxidative damage, seen in
early stages of some neurodegenerative diseases, can lead to a decrease in ATP synthesis,
which in turn would lead to a less reduced environment and an increase in free radical
production [56]. In some neurodegenerative diseases, especially in those where axonal
conduction is damaged, neurons tend to restore the conduction by increasing energy
consumption to restore axonal function [57]. In AD, low glucose metabolism is associated
with cognitive failure [58]; moreover, Rone et al. highlight the role of glycolysis to obtain
energy in cells under metabolic stress [59]. One of the key enzymes involved in glycolysis
is aldolase. In this work, we found a decrease (23%) in aldolase activity after treatment
of neurons with VitK3. Again, FP restored values to those found in control neurons
(Figure 3), agreeing with Lee et al., who also found an increase in aldolase activity with
S1P mimetics [54]; moreover, Geffin et al. found an upregulation of genes involved in
glycolysis, including aldolase, in cells exposed to HIV and treated with FP [60]. On the basis
of these findings, FP could be considered as a new therapeutic approach to the treatment of
neurodegenerative diseases showing a decrease in glycolysis, such as PD, AD, or MS [26].
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In the processing of glucose, the balance between glycolysis and PPP appears to be
important, as the PPP processing of glucose serves as a source of NADPH that in turn will
regenerate oxidized antioxidants such as glutathione and thioredoxin; thus, the exclusive
processing of glucose by the glycolytic pathway would produce a decrease in NADPH
availability, increase oxidative stress, and possibly cell death [64]. NADPH serves also
as a cofactor of NQO1 detoxifier activity, in the synthesis of fatty acids and myelin, in
neurotransmitter turnover, and in the maintenance of redox homeostasis [3,17].
G-6-PDH is one of the key enzymes in the PPP and it has been related to increases in
NADPH levels related to the improvement in redox homeostasis [65]; moreover, a decrease
of this enzyme has been found in neurodegenerative diseases such as PD [66]. Taking
in to account the relevance of this enzyme, we decided to study the level of G-6-PDH in
neuronal cultures after oxidative damage induced by VitK3 in the presence or absence of
FP. The results in Figure 5 show a decrease in the activity of G-6-PDH after incubation
with VitK3. This decrease was abolished when FP was included in the incubation media,
producing a great increase in G-6-PDH activity (threefold the control value). This marked
increase could be due to the stimulation in synthesis and translocation of Nrf2, an inductor
of PPP key enzyme synthesis, triggered by FP after the damage induced with VitK3, as
demonstrated previously by our group [17]. Moreover, other authors have previously
established the relation between Nrf2 synthesis and translocation, and the expression of
PPP key enzymes [67,68].
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Figure 5. FP increased the enzyme glucose-6-phosphate-dehydrogenase (G-6-PDH) reduced by VitK3.
G-6-PDH was measured in a homogenate of neurons after 2 hours of incubation with VitK3 in the
presence or absence of FP. Values represent mean and SD of at least five experiments per situation
performed in triplicate. (* p < 0.05 versus CO, $ p < 0.05 versus VitK3, # p < 0.05 versus VitK3+FP,
& p < 0.05 versus VitK3+FP+W).
3.4. Influence of S1P Receptors
Classically, FP is thought to develop its effects through the interaction with S1P
receptors. We can rule out the possibility of a direct FP–VitK3 pharmacologic interaction,
as these drugs do not share or overlap on mechanism of action with either of the enzymes
involved in its metabolization, and none of them have any known effect as inductors or
inhibitors of metabolic enzymes [69]. We demonstrated in this study the presence of S1P1
receptors in soma and axons of SN4741 neuronal cells (Figure 6).
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In order to determine the contribution of these receptor in the protective effect of FP,
we performed experiments in the presence of the selective S1P1 competitive antagonist W.
In the study of the influence of S1P receptors on the enzymes involved in redox balance, we
found intriguing results. Whereas the effect on SOD can be attributable to the interaction
of FP with S1P1 receptors—in such a way that we saw an increase in SOD by the increase
in free radicals triggered by VitK3, which was totally reverted in presence of FP—when
the S1P1 receptor was blocked with the antagonist, the beneficial FP effects disappeared,
free radicals increased again [17], and SOD values returned to those found in VitK3-treated
neurons (Table 1). The influence of S1P1 receptors on GPX was not so clear. In these
experiments, FP demonstrated exertion of its action, not only by its interaction with S1P1
receptors but also by other mechanisms, which could include its interaction with other
S1P receptor subtypes expressed in neuronal cells, such as S1P3 and S1P5. FP is a selective
but not a specific ligand for the S1P1; in fact, it binds with higher affinity (threefold) to
the S1P5 receptor (the less expressed in neurons) and with less affinity (fivefold) for the
S1P3 [70]. Unfortunately, there are not enough selective compounds to study receptors
other than S1P1. Assuming that FP effect was not due to the interaction of FP with specific
S1P receptors, we could still be in the presence of non-receptor mechanisms. These would
include an increase in expression of Nrf2, heme oxygenase 1 (OH1), and thioredoxin, and
also an increase in Nrf2 translocation to the nucleus [17], with these factors, especially Nrf2
and OH1, being important to increasing antioxidant enzymes such as GPX. Something
similar occurred with CAT, where no clear results on the influence of S1P1 were obtained.
In these experiments, we did not see effects of VitK3 incubation on CAT activity, nor with
the addition of FP. Interestingly when the S1P1 receptor was blocked, we found a decrease
in the activity of this enzyme without a clear explanation; however, we could argue that
the decrease could have been related to the increase in SOD and GPX previously found,
which would reduce the H2O2 and in turn would decrease CAT [71]. In the study of protein
nitrosylation, we found a similar behavior to that in SOD. Neurons incubated with VitK3
showed an increase in protein nitrosylation that was reverted in the presence of FP—the
blockade of S1P1 receptor abolished FP beneficial effects, increasing nitrosylation again to
levels close to those found in VitK3-treated neurons, agreeing with other authors [72]. All
the effects of FP on glycolysis were mediated through its interaction with S1P1 receptors,
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as all of these effects disappeared when the S1P1 antagonist was present, being affected the
basal glycolysis, glycolytic capacity, glycolytic reserve, and the capacity to maintain the
aldolase activity. This finding was common with other authors who also found the need of
interaction of FP with its receptor to develop its glycolytic protective actions [54,60]. In the
study of G-6-PDH activity, the effect of FP was also mediated by the interaction with its
specific S1P1 receptor, as the increase in G-6-PDH activity was totally abolished when the
S1P1 antagonist was present in the incubation media.
4. Conclusions
Overall, our data support that in extreme neuronal situations such as in neurode-
generative diseases, where damaged mitochondria are unable to cover the ATP needs
and the oxidative environment turns threatening for the cells, other sources of ATP and
antioxidants need to be used. Our results show, on one hand, a beneficial effect of FP,
increasing glycolytic and pentose phosphate metabolism and hence ATP production and
redox buffering capacity, which are important factors against neurodegeneration. On the
other hand, FP also exerts a beneficial effect on mitochondrial oxidative damage, which
would improve neuronal condition by improving mitochondrial function and restoring ox-
idative balance in neurons. Both actions would make this drug a potential therapeutic tool
for the treatment of neurodegenerative processes, either to slow progression or alleviate
symptoms.
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